Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Antibody production is majorly done for neutralizing or eliminating the antigens or pathogens. The production is mostly based on different level and are employed for the producing antibody. The rising rate of cancer and other disease has led the demand for the antibody production market. Besides increasing number of biotechnology and pharmaceutical manufacturer across the globe has created a new growth avenue for the market. The developing demand for antibody production from various end user is expected to boost the market growth.
The market is driven by increasing adoption of targeted immunotherapy among cancer patients as the therapy improve immune mediated regulatory effects against tumors and further helps to improve the overall survival. Likewise, increasing R&D expenditure in pharmaceutical and biotechnological companies is boosting the demand across globe. Also, rising number of fast track and orphan drug designations is the key factor to boost the market growth as it helps treating serious conditions. This features are anticipated to fuel the market growth.
The exclusive COVID 19 impact analysis report by Axiom MRC provides a 360 degree analysis of micro and macro-economic factors on the antibody production market. In addition, complete analysis of changes on the antibody production market expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on global economies, international trade, business investments, GDP and marketing strategies of key players present in the market. COVID-19 had a positive impact on market as the demand for the production of new antibody was accelerated specifically for corona viruses.
The antibody production market comprises of different market segment like process, end user, class and geography.
By process, the antibody production includes key segment of upstream processing, downstream processing, ion exchange (iex) chromatography resins, hydrophobic interaction chromatography (hic) resins, multimodal chromatography resins, and filtration. Further, upstream processing includes bioreactors and consumables. Bioreactors is further sub segmented to large-scale bioreactors and single-use bioreactors (subs). Likewise, consumables includes media and reagents and buffers. Also, downstream processing is bifurcated to chromatography instruments and chromatography resins. Additionally filtration includes filtration systems and filtration consumables and accessories. The downstream processing is expected to dominate in the market owing to efficient product production, with reduce cost expenditure. Furthermore, downstream processing helps in recovery and purification of products which add an added benefit antibody product production at different operational stages. Also, upstream processing is expected to hold second position in market due to its higher yield, cost savings, efficient facility utilizations and increase speed of antibody product production.
The antibody production market finds its end use in pharmaceutical and biotechnology companies, diagnostic laboratories and research institutes. The end use leading segment is expected to be pharmaceutical and biotechnology companies owing to increasing requirement of segment for the production of antibody based on different process. Also, growing number of manufacturer in antibody production is boosting the segment growth. In addition, research institutes is anticipated to growth at significant pace attributing constant research and development for new antibody according to different disease type. Besides, increasing funding for projects and innovation is fueling the demand for segment thereby accelerating the antibody production market.
The antibody production by class is available in market according to monoclonal antibodies, murine, chimeric, humanized and polyclonal antibodies. The monoclonal antibodies segment has gained the major market share in antibody production. The growth is due to increasing research and investment for the production of new products. Likewise, adoption for monoclonal antibodies among population is driving segment growth. On the other hand, polyclonal antibodies is expected to growth at significant pace due to easy production process, product availability in low cost.
The global antibody production market is studied for the following region North America, Europe, Asia-Pacific and Rest of the world (RoW). North America is anticipated to lead in the global market owing to increasing research and development on antibodies production using different technique based on biotechnology and pharmaceutical. Besides, rising government expenditure and growing incidence of different disease has led the demand for antibody production market in the region. Likewise, Asia Pacific is expected to witness exponential growth due to presence of major manufacturer in region. Also, demand of antibody production due to rising cases of cancer is key factor for the growth of market. Additionally, Europe is likely to contribute healthy growth in the market.
The key players in antibody production market are GE Healthcare (General Electric Company), Merck KGAA, Thermo Fisher Scientific, Inc., Sartorius AG, Pall Corporation (Danaher Corporation), Sigma-Aldrich Corporation (Merck KGAA), Eppendorf AG, Cellab GmbH, Integra Biosciences AG and Fibercell Systems Inc. among others.
Recent Developments:
May 2021: Roche India had announced that Central Drugs Standards Control Organization has provided the emergency use authorisation for Roche’s antibody cocktail (Casirivimab and Imdevimab) in India. The emergency use authorization will now enable Roche Company to import the global manufactured products batches to India. It will be marketed and distributed in India with strategic partnership with Cipla Limited
April 2021: Harbour BioMed had presented a newly discovered fully human anti- B7H7 monoclonal antibody at American Association for Cancer Research. The anti- B7H7 monoclonal is a novel immune oncology antibody with potent anti-tumor activity generated using HBM proprietary H2L2 Harbour Mice platform.
October 2020: IAVI and Serum Institute of India had announced an agreement with Merck KGaA, Germany to develop SARS CoV-2 neutralizing monoclonal antibodies (mAbs) and is co- invented by IAVI and Scripps Research as innovative interventions for COVID-19 pandemic.
February 2019: Moderna Inc. had announced the dosing of the first subject phase 1 clinical trial evaluating the safety and tolerability of escalating doses of mRNA -1944 via intravenous infusion in healthy adults. This is the first monoclonal antibody encoded by mRNA to be dosed in human.
The report analyses the antibody production market based on by process, end user, class and geography. By process, the antibody production includes key segment of upstream processing, downstream processing, ion exchange (iex) chromatography resins, hydrophobic interaction chromatography (hic) resins, multimodal chromatography resins, and filtration. The antibody production market finds its end use in pharmaceutical and biotechnology companies, diagnostic laboratories and research institutes. The antibody production by class is available in market according to monoclonal antibodies, murine, chimeric, humanized and polyclonal antibodies. The global antibody production market is studied for the following region North America, Europe, Asia-Pacific and Rest of the world (RoW).
Why to buy this report:
